Press Releases

Date Title  
Toggle Summary Aimmune Therapeutics Expands Scientific Advisory Board With Appointments of George du Toit, M.B., B.Ch., and Wayne Shreffler, M.D., Ph.D.
— New Members Join International Board of Leading Academic Experts in Allergy and Immunology — — Prof. du Toit Is Lead Author of Landmark LEAP and LEAP-On Studies on Prevention of Peanut Allergy in Young Children — — Dr. Shreffler Is a Renowned Expert on Immunologic Mechanisms of Food Allergy —
Toggle Summary Aimmune Therapeutics Announces Presentations at 2018 AAAAI-WAO Joint Congress
BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 12, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will present data during a late-breaking oral abstract session and in poster
Toggle Summary Aimmune Therapeutics Broadens and Extends Supply Agreement With Golden Peanut and Tree Nuts for AR101 for Peanut Allergy
— Newly Expanded Global Agreement Secures Exclusive Supply Relationship through 2033 — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 10, 2018-- Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced an
Toggle Summary Aimmune Therapeutics Announces 2018 Outlook, Including Upcoming Data from Pivotal Phase 3 PALISADE Trial of AR101 for Peanut Allergy
— PALISADE Completed in 2017; Topline Results Anticipated in February — — Late-Breaking Abstract Presentation at the 2018 American Academy of Allergy , Asthma & Immunology–World Allergy Organization Joint Congress in March — — PALISADE Follow-On Study, ARC004, Fully Enrolled — — RAMSES Real-World
Toggle Summary Aimmune Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference
— Presentation on Wednesday, January 10, 2018 , at 7:30 a.m. Pacific Time — BRISBANE, Calif. --(BUSINESS WIRE)--Jan. 3, 2018-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CEO Stephen Dilly ,
Toggle Summary Aimmune Therapeutics to Participate in the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on December 14
BRISBANE, Calif. --(BUSINESS WIRE)--Dec. 7, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that Chief Financial Officer Eric Bjerkholt will participate in a fireside chat at the BMO Capital
Toggle Summary Aimmune Therapeutics to Host Investor Symposium on Peanut Allergy Treatment with Leading Expert Allergists on Friday, December 1
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 20, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host an Investor Symposium in New York City on December 1, 2017 .
Toggle Summary Aimmune Therapeutics Announces Third Quarter 2017 Financial Results and Planned Retirement of CEO by the End of 2018
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 6, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2017 .
Toggle Summary Aimmune Therapeutics to Participate in Four Investor Conferences in November
BRISBANE, Calif. --(BUSINESS WIRE)--Nov. 1, 2017-- Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in four upcoming investor
Toggle Summary Aimmune Therapeutics Announces Publication in The Journal of Allergy and Clinical Immunology: In Practice of Positive AR101 Data from ARC001 Phase 2 Clinical Trial
— Study Showed that Six Months of AR101 Treatment Could Significantly Reduce Clinical Reactivity to Peanut in Approximately 80 Percent of Subjects Enrolled — — First Peer-Reviewed Publication of Efficacy and Safety of an Industry-Sponsored Food Allergy Trial — BRISBANE, Calif.